The Department of Health and Social Care aims to amend the Human Medicines Regulations 2012, thereby enabling pharmacy technicians to provide and administer
specific medicines through a patient group direction. In line with this initiative, the Department introduced a six-week consultation to assess whether registered
pharmacy technicians should be authorised to dispense medicines using a PGD.
The proposals, backed by all four Home Nations, apply exclusively to registered pharmacy technicians. Meanwhile, this coverage will extend to include pharmacy
technicians in Northern Ireland upon their achievement of registered professional status.
"The proposed statutory instrument, presently applicable in England, Scotland, and Wales would offer 'clear benefits,' especially in areas such as vaccination
and the provision of oral contraception and EHC," the DHSC said.
According to the Department, facilitating registered pharmacy technicians to execute PGDs might amplify their workload, yet it could simultaneously enhance
overall efficiency and cost-effectiveness for pharmacy teams by optimising the utilisation of skill diversity.
The UK pharmaceutical industry experienced a substantial increase in public trust and favourability during the Covid-19 pandemic, according to a new poll.
This trend appears to be persisting with the study showing a generally favourable view of the sector.
The recent survey, conducted by Ipsos and commissioned by Association of the British Pharmaceutical Industry (ABPI), represents the third instalment in a series
that began in 2021. This ongoing study targets members of the public, healthcare professionals, and parliamentarians.
The study once again underscored a favourable perception of the sector with 67 per cent of respondents recognising that the pharmaceutical industry produces safe
and effective medicines using cutting-edge technologies. Moreover, a majority agrees that it is a highly innovative field.
Seven out of 10 people also trust the sector's readiness to address future pandemics, even as media attention on pharmaceutical companies returns to pre-pandemic
levels. However, concerns arise regarding limitations in accessing new medicines due to cost pressures.
The Hyderabad Police are actively searching for UK-based pharmacist M. Ajith Kumar, who is suspected of involvement in a plot to poison his estranged wife's
family in Hyderabad by contaminating their spices with arsenic. While the accused allegedly succeeded in fatally poisoning his mother-in-law through a slow method,
timely arsenic testing saved the lives of others.
In late June, a newlywed woman in her 30s visited a Guntur-based doctor, complaining of intense burning, tingling, and numbness in her hands and feet. The
neurologist's keen observation foiled the alleged sinister plot of Ajith Kumar, suspected of using his chemical expertise to harm his wife and her family.
Presently, the police are actively searching for M. Ajith Kumar, who is currently in London, in connection with the murder plot. Furthermore, the Hyderabad police
have apprehended six individuals from the city who were complicit in his nefarious scheme.
The investigation gathered key information from arrested suspects, including D. Vinod Kumar, a UK-based IT professional from Andhra Pradesh. Vinod Kumar's involvement
in UK software projects provided by Ajith Kumar generated a substantial monthly income, leading him to assist Ajith in his plot against his estranged wife's family.
RPS Scotland has named Fiona McIntyre as its new Policy and Practice Lead. With a background in hospital pharmacy, McIntyre will be responsible for policy
development and professional support at RPS Scotland, and is set to assume her new role in early October.
McIntyre will assume a leadership role for specific projects across Great Britain, collaborating with the Policy and Practice Leads in England and Wales, RPS
Scotland said in a statement. Her responsibilities include representing pharmacists in working groups and meetings, engaging with pharmacists and pharmacy
organisations, and supporting the RPS Director for Scotland.
"During my career in NHS Scotland, I have advocated for pharmacy teams whenever possible," said McIntyre. "I am passionate about the profession's role in the
safe and effective use of medicines, and I'm privileged to join the RPS. I look forward to promoting pharmacy in Scotland and helping our profession reach its
full potential."
"I'm pleased that Fiona will be joining the RPS Scotland team as our policy lead," said Laura Wilson, Director for RPS Scotland. "Fiona's experience will be
invaluable to the role, and the whole team looks forward to her starting with us in October."
Novo Nordisk, the Danish drug manufacturer, has launched Wegovy, a weight-loss drug, in the UK market. This semaglutide injection will be available
through specialist NHS weight management services for those who meet the National Institute for Care and Excellence (NICE) criteria or privately through
registered healthcare professionals.
Novo Nordisk allocated a portion of the available supply of Wegovy for NHS services, while confirming the existing shortage of semaglutide and projecting
continued constraints in the foreseeable future. The drug can be obtained through the NHS and is additionally accessible for private purchase at pharmacies in the UK.
The pricing for a one-month supply varies, ranging from £73.25 to £175.80, depending on the dosage.
"We are committed to expanding treatment options for individuals with obesity and share the Government's goal of improving access to obesity care in areas of high
unmet medical need," the company said in a statement. "We are closely monitoring Wegovy demand and collaborating with regulators and providers to ensure access
to and continuity of treatment for people living with obesity."
The General Pharmaceutical Council's Fitness-to-Practise (FtP) committee has reversed its earlier decision ruling that a London pharmacist's statement,
attributing the Grenfell tragedy to "Zionist supporters of the Tory party," amounted to the propagation of anti-Semitic tropes.
In an initial 2020 hearing, the FtP committee found that a set of remarks delivered by Nazim Hussain Ali, Managing Partner of Chelsea Pharmacy Medical Clinic,
through a megaphone to a crowd assembled at a Palestinian rights rally in central London in 2017 were deemed "grossly offensive," but not classified as anti-Semitic.
Ali admitted his comments were offensive, but he was cleared of accusations of antisemitism and received a first warning on November 5, 2020.
However, the High Court overturned this decision in June 2021 following an appeal by the Professional Standards Authority as the Judge found evidence of
a "serious procedural or other irregularity" in the FtP committee's decision and instructed the GPhC to reopen the case.
Several medium-sized pharmacy chains and multiples in Scotland are increasing in size by purchasing numerous LloydsPharmacy sites that were closed last month.
The Pharmacists Defence Association (PDA) Regional Committees met to dwell on the issues faced by the community pharmacists across the UK. The PDA's Scottish
regional committee highlighted the impact of Lloyds Pharmacy's closure in their third committee meeting of 2023.
It said: "Davidsons who have purchased various businesses in Tayside. Rowlands has purchased 30 branches across central Scotland and the PDA has been in touch
with members affected. These members will be supported to ensure that they are properly subject to a TUPE transfer (Transfer of Undertakings Protection of Employment)
as they should be when a business changes ownership."
Most discussion amongst the Scottish Regional Committee members was around community pharmacy. Reports suggest that negotiations between the Scottish government
and the pharmacy owners' body, Community Pharmacy Scotland (CPS) have broken down. As the independent voice of the frontline employed and locum pharmacists that
deliver the contract, the PDA wants to see an agreement found for the benefit of patients, taxpayers, and health professionals.
Errors of any kind in medical settings can have dire consequences for patients and healthcare systems. Unfortunately, negligence, misdiagnosis, and
medication errors aren't uncommon in the UK.
In this article, we discuss the nature of medication errors in the NHS, outline potential causes, and delve into how and why technology could be turning the tide
on the issue.
Prevalence and consequences of medication errors
Medication errors are incidents involved with the administering, prescribing, dispensing or monitoring of medicine to patients. It can happen at many different
steps in the healthcare process and by any medical professional in the system. Many cases are avoidable.
According to analysis from BMJ, there are an estimated 237 million medication errors made in England every year. The majority of these are minor errors, but 1 in 4
cases has the potential to cause moderate to serious harm to patients.
Not only do these errors cost the NHS significantly, at almost £100 million every year, but there is a shocking cost to public health. Lives are being lost because
of medication errors which is unforgivable and tragic for the families involved.
Drains on NHS resources have widespread impacts on public health and the operations of healthcare organisations up and down the country. Individual errors and
mistakes may seem inconsequential (in minor cases), but they all add up in the big picture to a significant concern for policymakers.
Approximately 25 million GP appointments and 5 million A&E visits are utilised each year for self-treatable illnesses. If these individuals chose to self-treat
using over-the-counter (OTC) medications, the potential savings for NHS could amount to at least £1.7 billion annually, according to a research commissioned by
Proprietary Association of Great Britain.
The study, conducted by analysts at Frontier Economics, revealed that embracing self-care could bring an additional economic benefit of £350 million annually, as
employees would avoid unnecessary time off from work for medical appointments.
Apart from the savings resulting from the increased OTC medicine use, the report emphasises the potential benefits of reclassifying more prescription-only
medications (POMs). A mere 5 per cent reduction in NHS prescribing levels and spending could lead to an annual cost-saving of £1.4 billion, encompassing both
prescription costs and GP appointments, it said.
"This substantial amount could greatly alleviate financial pressures on the NHS and offer essential resources for recruiting and training much-needed healthcare
professionals."
The Health and Social Care Committee (HSCC) has announced the appointment of six specialists to scrutinise the government's progress made on its commitments
to pharmacy services in England on Wednesday (26 April).
"They will work alongside the core members of the Expert Panel to produce a report evaluating Government progress across nine of the Government's own commitments
across the four areas. A CQC-style rating from "inadequate" to "outstanding" will be awarded against each specific pledge with a final overall rating given," said
DHSC.
Professor Dame Jane Dacre, Chair of the Expert Panel, said: "The role of pharmacy in delivering care whether in hospital, the community or primary care has never
been more important.
"The Government has made a number of commitments aimed at improving pharmacy services and we'll be looking at the progress to achieve these targets.
"In the process of our evaluation we'll be hearing from stakeholders from across the industry, including the pharmacy workforce and NHS and independent providers
of pharmacy services. We'll be considering pledges covering frontline services as well as the education and training of the workforce."
National Pharmacy Association (NPA) chief executive, Mark Lyonette, is one of six panel members with specialist expertise in pharmacy. They will work alongside five
standing members who are all renowned healthcare policy experts and professionals. Professor Dame Jane Dacre will chair.
The International Pharmaceutical Federation (FIP) has offered a new resource to help countries self-assess readiness of their regulations to enable
pharmacist-delivered vaccination services and, where needed, to implement such regulations.
Developed by FIP's Regulators Advisory Group, it covers broad pharmacist-led roles related to vaccination from supply chain management to administration and
prescribing.
"This new resource from FIP is based on the experiences of professional regulators in countries where pharmacy-led vaccination has been successfully introduced
and regulated. With it, we aim to support regulators, policymakers and national organisations in developing strategies or enabling regulatory frameworks in
countries where the pharmacy workforce has a limited role in vaccination strategies so that it can contribute further to the global imperative of improving
immunisation coverage," said Brett Simmonds, group chair.
The "Pharmacy-led vaccination services: Regulatory self-assessment and implementation tool" aims to help identify strengths and areas for improvement in order to
inform vaccination policy and planning efforts.
In a rapidly evolving and competitive landscape, the pharmaceutical industry faces unique challenges when it comes to marketing its products and services.
With stringent regulations, complex target audiences, and a need for trust and credibility, pharma companies need to employ effective marketing strategies to stand
out in the crowd. In this blog article, we will explore some key marketing strategies for the pharma industry that can help boost their visibility, engage their
target audience, and drive business growth.
UNDERSTANDING THE UNIQUE LANDSCAPE
The pharma industry operates in a highly regulated environment, where compliance and ethical considerations play a crucial role. Before diving into marketing
strategies, it is essential to have a deep understanding of the industry's dynamics and the target audience. Researching the market, identifying patient needs,
and studying the competitive landscape are vital steps in developing an effective marketing plan.
EMBRACING DIGITAL TRANSFORMATION
Digital transformation has revolutionized marketing across industries, and the pharma sector is no exception. Embracing digital channels and technologies can
significantly enhance the reach and impact of marketing efforts. Pharma companies can leverage social media platforms, create engaging content, and build online
communities to connect with patients, healthcare professionals, and other stakeholders. Implementing robust digital marketing strategies allows for personalized
messaging, real-time communication, and targeted campaigns that resonate with the target audience.
The Health and Social Care Secretary Steve Barclay has proposed a new £30 million fund to speed up the adoption of innovative medical technology in the NHS.
He confirmed the plan today at the Conservative Party Conference 2023 in Manchester.
Mr Barclay said that virtual wards will help healthcare professionals embrace new technology to improve patient care.
He said: "It is vital that clinicians have access to the latest technology to save staff time, deliver high-quality care and help cut waiting lists - one of the
government's top five priorities.
"This investment will see the latest tech innovations rolled out across the NHS. From virtual ward beds to wearable medical devices, patients will be better
supported, and we will ease pressures on hospitals this winter.
"We're preparing for this winter earlier than ever before including delivering thousands more hospital beds and hundreds of new ambulances."
The lessons from Covid crisis applied in the future through collaboration can create a better integration between GP practices, hospitals and community
pharmacies, Pharmacists Defence Association (PDA) has proposed.
Stating that a more integrated healthcare system could enable pharmacists to provide effective and more efficient care to patients, the PDA proposed a model where
at least two pharmacists would be working in each community pharmacy, empowered, and enabled with two-way referral pathways, having more clinical input and full
access to patient records.
"Such an environment could not only help to improve communications between health professionals and increase access to services for patients, but would support
the NHS to operate more effectively."
Whether it's the effects of the coronavirus pandemic and those suffering with long Covid, or the financial pressures of rising living costs, these hard times
can affect absolutely anyone's mental health.
Mental health problems have worsened across all age-groups in the last few years, from lack of social interaction, unexpected bereavements or the significant impact
of a physical injury or long-term illness taking its toll on mental wellbeing - these challenging experiences and situations that we face throughout life leave a
big strain on the population.
Ultimately, there is an urgent need to reduce rising levels of mental ill-health in our society. As a pharmacist with 25 years' experience in healthcare, I feel I
have an obligation to my patients to support them with their healthcare needs, and mental health should be treated just the same as physical health.
Despite efforts to improve NHS mental health services, patients may still not be receiving the appropriate immediate care as they are often provided with online
counselling or an App for long-term support (online support introduced since the pandemic).
Community pharmacists are in a unique position to be advocates for patients with mental illness as they are the healthcare professionals' patients see most often.
This is a good opportunity for pharmacists to speak to patients face-to-face and give them advice in a more practical way rather than potentially waiting weeks for
an GP appointment.
The Pharmacists' Defence Association (PDA) has raised concerns over "certain elements" of the Pharmaceutical Society of Northern Ireland (PSNI)'s consultation
on pharmacy staffing levels.
PSNI recently consulted on its draft guidance for pharmacy staffing levels which sets out to explain what pharmacy owners and superintendents must do to ensure that
each pharmacy has enough skilled and qualified staff. This includes having an appropriate skill mix, to provide safe and effective pharmacy services which comply
with the standards.
PDA said that the role of the 'responsible pharmacist' has not been "fully acknowledged" and that more clarification is needed.
The association has made a few recommendations to PSNI that includes: the guidance must explicitly recognise the statutory role of the responsible pharmacist and
their authority in securing the safe operations within the pharmacy.
"The guidance should specify that pharmacy owners and superintendents must ensure that they do not set incentives or targets which may compromise the professional
judgement of staff."
It also recommended that unregistered staff (including unregistered managers) are accountable firstly to the responsible pharmacist for any activity involving the
clinical care of patients (for example unregistered managers must not interfere in diary bookings for vaccinations).
Chair of the Health and Social Care Committee Steve Brine MP has called on community pharmacy contractors to join a newly launched a parliamentary 'call for
evidence' which will look into 'prevention' as a key to the future of the NHS.
A former pharmacy minister and keen supporter of the sector, Mr Brine has called on all community pharmacists to "make their contribution count" by taking part in a
major inquiry which will remain open for submission until Wednesday 8 February 2023 and will also involve general practitioners, nurses and other health professionals.
Community pharmacists can submit their proposals written under 750 words, outlining what they think are the issues around prevention the parliamentary body should
explore, why these issues deserve the Commons Select Committee's attention, and how government policy could be developed or improved to address them.
The submissions will then be used to help the committee decide where it should focus its attention in the later stages of the inquiry on prevention, which is a vital
part of the NHS Long Term Plan.
The International Pharmaceutical Federation (FIP) in a report of a meeting of an international insight board published on Friday (27 January) highlighted the
potential for pharmacists to close the existing gender gap in pain management.
The insight board, assembled by FIP in Seville, Spain, in September 2022, was co-chaired by FIP vice president Professor Parisa Aslani. "Research indicates that pain
experienced by women is underestimated and undertreated. Alarmingly, in addition to receiving less effective pain relief, evidence suggests that women with pain are
more likely to be prescribed antidepressants," Prof. Aslani said.
The insight board attributed much of this "gender pain gap" to implicit biases and put forward the view that pharmacy curricula and continuous professional
development programmes must be able to provide adequate self-awareness and training to enable pain management without any bias. It also suggested ways in which
pharmacists could be supported in addressing the gender pain gap in their practice.
The Welsh chapter of the Royal Pharmaceutical Society, along with ten other royal colleges and professional bodies, have renewed calls for the urgent
transformation of mental health services to address increasing demands on the NHS in Wales.
Representatives of the Royal College Mental Health Expert Advisory Group joined members of the Senedd in Cardiff to outline the work of the group over the past
year and to explain why a well-trained, fully supported and equipped multi-disciplinary workforce is critical for the development of care for people with mental
health conditions.
To make sustainable change happen, the group is calling for a greater focus by the Welsh government and NHS Wales on the following:
The critical changes needed to improve the delivery and structure of mental health services across Wales in community, hospital and specialist secure settings.
Parity of access to mental health services for the most vulnerable patients, ensuring they have equal access opportunities that vulnerable patients would receive for
physical health conditions.
There is no doubt that the pandemic has changed the way healthcare professionals work within the primary care setting. The advent of Covid-19 meant that we all
had to rapidly modify the way we supported and met the needs of patients, some of whom saw the services they usually took for granted, virtually cease overnight.
There are around 15 million people in England living with long-term health conditions including asthma. These people have the greatest healthcare needs of the whole
population with 50 per cent of all GP appointments and 70 per cent of all bed days taken by this cohort of patients, and their treatment and care absorbing 70 per
cent of acute and primary care budgets in England.
This situation isn't going to improve any time soon. In the past, most people had a single condition, today multi-morbidity is becoming the norm. At the start of the
pandemic, the Royal College of General Practice and British Medical Association issued guidance to practices on prioritising workload. This included the importance
of maintaining long-term condition reviews in asthma, COPD and diabetes, along with appropriate transition of at-risk warfarin patients. These reviews were deemed as
essential workstreams for patients considered to be at high risk.
Traditionally, the unique skills set of a pharmacist has meant that we have played a major role in supporting these patients. I work with a team of over 90 clinical
pharmacists who, in partnership with individual practices, PCNs, CCGs and STPs, help with the long-term management of people with chronic conditions. But the onset
of Covid-19 meant that we now had to plug a potential gap in service provision, and quickly.